Laboratory Medicine
Test Directory / Oestradiol
Oestradiol
Brown clotted serum, gel barrier
Test | Oestradiol |
---|---|
Common Abbreviations | E2, OES |
Profile | NA |
Tube type | Brown clotted serum, gel barrier |
Clinical Indication | Measurement of oestradiol can be useful for assessing ovarian function and monitoring follicular development in assisted reproduction. Elevated levelsin females may indicate ovarian hyperfunction related to pregnancy or assisted reproduction. Decreased levels maybe related to menopause or hypothalamic-pituitary axis dysfunction. |
Specimen Type | Blood |
Sample type | Serum |
Minimum Volume | 0.5mL If requesting more than 10 tests please send an additional brown clotted serum sample. |
Special Precautions | No special requirements |
Stability | 24 hours at 20 - 25°C, 2 days at 2 - 8°C and 6 months at -20°C |
Turnaround Time | Inpatient: 24 hours Outpatient/ GP: 24 hours |
Laboratory | York and Scarborough |
Reference Interval | Male: < 223 pmol/L Female: Follicular phase: < 854 pmol/L Ovulation: 151 - 1461 pmol/L Luteal phase: 82 - 1251 pmol/L Post-menopausal < or equal to 505 pmol/L (Quoted by the manufacturer) |
Limitations | Analysis should not be performed on haemolysed, icteric or lipaemic samples. The assay is unaffected by biotin < 147 nmol/L or < 36 ng/mL. No interference was observed from rheumatoid factors up to a concentration of 1200 IU/mL. No interference was observed from IgG < 7.0 g/dL; IgA < 0.4 g/dL; IgM < 1.0 g/dL Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration. In vitro tests were performed on 16 commonly used pharmaceuticals. No interference with the assay was found. Due to the risk of cross reactivity, this assay should not be used when monitoring oestradiol levels in patients being treated with Fulvestrant. In rare cases, interference due to extremely high titres of antibodies to analyte specific antibodies, streptavidin or ruthenium can occur. |
Notes |